Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan info@chordiatherapeutics.com



This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release> October 3, 2022

Chordia Therapeutics Director and Statutory Auditor Appointments

Kanagawa, Japan,

October 3, 2022 – Chordia today announced the appointment of members to its Board of Director and Statutory Auditor following approval at the Extraordinary General Meeting of Shareholders.

<Director>

Outside Director Akihiko Shimauchi

<Statutory Auditor>

Outside Statutory Auditor Yukari Nishikata

About Chordia Therapeutics

Chordia is a clinical stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, engaged in the research and development of novel therapies for cancers. Chordia's lead asset CLK inhibitor CTX-712 is under Phase 1 clinical study in Japan. CTX-712 potentially targets the vulnerability of cancer, and is expected to deliver benefit to patients of various types of cancer. In addition to CTX-712, Chordia is engaged in the research of several preclinical assets, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

Established: November 2017

Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa,

Kanagawa 251-0012, Japan

Representative: Hiroshi Miyake, Representative Director Website: https://www.chordiatherapeutics.com/en/

For more information, contact Kentaro Kume, IR: info@chordiatherapeutics.com